Find out more …

Filter results
E.g., 28/06/2022
E.g., 28/06/2022
​ROVI reports operating revenue growth of 57% and net profit growth of 123%
Moderna and ROVI Pharma Industrial Services, S.A.U. today announced a recall of one lot (lot #000190A) of the Moderna COVID-19 vaccine (Spikevax®)
The achievement of this important milestone responds to the Environmental and Social Sustainability Policy of the Group and to the efforts that performs to reduce the environmental impact of all its activities.
ROVI reports operating revenue growth of 54% and net profit growth of 151%
Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone